HUMANIZED ANTI-TAU(pS422) ANTIBODIES AND METHODS OF USE

Patent metadata

Field	Value
Publication number	US-2016376352-A1
Application number	US-201615189711-A
Country	US
Kind code	A1
Filing date	Jun 22, 2016
Priority date	Jun 24, 2015
Publication date	Dec 29, 2016
Grant date	—

Abstract

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

First claim

1 . A humanized antibody that specifically binds to human Tau(pS422), wherein the antibody comprises
in the heavy chain variable domain the HVRs of SEQ ID NO: 08, 09 and 10, and in the light chain variable domain
the HVRs of SEQ ID NO: 71, 73 and 15;
the HVRs of SEQ ID NO: 70, 72 and 15;
the HVRs of SEQ ID NO: 12, 14 and 74.

2 . The humanized antibody according to claim 1 , comprising
a) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 67; b) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 66; c) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 68.

3 . The humanized antibody according to claim 1 , wherein the antibody is effector function silent.

4 . The humanized antibody according to claim 1 , wherein the antibody
i) specifically binds to a polypeptide that has the amino acid sequence of SEQ ID NO: 03, and/or ii) does not bind to full length human Tau (SEQ ID NO: 01) at 1 μg/mL, and/or iii) specifically binds to full length human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02), and/or iv) specifically binds to aggregates of human Tau phosphorylated at the serine at position 422 (SEQ ID NO: 02).

5 . The humanized antibody according to claim 1 , wherein the antibody has an EC 50 value for
a) the human Tau(pS422) fragment that has the amino acid sequence of SEQ ID NO: 03 of 6 ng/mL or less, and/or b) the full length human Tau(pS422) that has the amino acid sequence of SEQ ID NO: 02 of 4.5 ng/mL or less, and/or c) aggregates of human Tau (pS422) that has the amino acid sequence of SEQ ID NO: 02 of 30 ng/mL or less, and/or d) the human Tau that has the amino acid sequence of SEQ ID NO: 01 and that has the amino acid mutation S422A of 125 ng/mL or less.

6 . The humanized antibody according to claim 1 , wherein the antibody specifically binds to human Tau(pS422) (SEQ ID NO: 02) and does not bind to human Tau (SEQ ID NO: 01).

7 . The humanized antibody according to claim 1 , wherein the antibody is
a) a full length antibody of the human subclass IgG1; b) a full length antibody of the human subclass IgG4; c) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G; d) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G; e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain; or f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

8 . A bispecific antibody comprising
i) a first binding site selected from
a) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 66;
b) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 67; or
c) a heavy chain variable domain of SEQ ID NO: 65 and a light chain variable domain of SEQ ID NO: 68,
and ii) a second binding site selected from
a) a heavy chain variable domain of SEQ ID NO: 82 and a light chain variable domain of SEQ ID NO: 85;
b) a heavy chain variable domain of SEQ ID NO: 83 and a light chain variable domain of SEQ ID NO: 85; or
c) a heavy chain variable domain of SEQ ID NO: 84 and a light chain variable domain of SEQ ID NO: 85.

9 . A pharmaceutical formulation comprising the antibody according to any one of claim 1 or 8 and optionally a pharmaceutically acceptable carrier.

10 . (canceled)

11 . A method of treating a subject suffering from Alzheimer's Disease, the method comprising administering to the subject an effective amount of an antibody according to any one of claim 1 or 8 .

12 . A method of treating a subject suffering from prodromal Alzheimer's Disease, the method comprising administering to the subject an effective amount of an antibody according to any one of claim 1 or 8 .

13 . (canceled)

14 . A method for reducing Tau(pS422) induced neurodegeneration in a subject comprising administering to the subject an effective amount of an antibody according to any one of claim 1 or 8 .

15 . A method of treatment comprising administering an antibody according to any one of claim 1 or 8 for treating Alzheimer's disease, for treating prodromal Alzheimer's disease, for treating mild Alzheimer's disease, for reducing Tau(pS422)-induced neurodegeneration, for maintaining cognition and function, for slowing the rate of cognitive and functional decline, or for slowing down the rate of neurofibrillary tangle accumulation.

Assignees

• Hoffmann La Roche

Inventors

• Dengl Stefan
• Emrich Thomas
• Georges Guy
• Goepfert Ulrich
• Grueninger Fiona
• Hugenmatter Adrian
• Jochner Anton
• Kettenberger Hubert
• Moelleken Joerg
• Moessner Ekkehard
• Mundigl Olaf
• Niewoehner Jens
• Schlothauer Tilman
• Molhoj Michael
• Brady Kevin

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/31

  multispecific · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title